Castle Biosciences posts Q3 revenue up 24% and lifts full‑year guidance
Castle Biosciences reported third‑quarter 2026 revenue of $102.9 million, a 24% increase year over year, driven by a 47% jump in TissueCypher test volume. The company posted a net loss of $4.1 million and adjusted EBITDA of $12.7 million, while generating $19.7 million of operating cash. It raised its full‑year 2026 revenue outlook to $385‑$395 million, up from the prior $365‑$375 million range.
Why it matters
The company says the higher guidance reflects continued strong demand for its core dermatology tests, implying better earnings prospects for the remainder of 2026. Investors will see a larger revenue target and a modest improvement in profitability metrics.
Key facts
- 1Q3 2026 revenue was $102.9 million, up 24% from Q3 2025. prnewswire.com
- 2TissueCypher test report volume increased 47% year over year in Q3 2026. prnewswire.com
- 3Full‑year 2026 revenue guidance was raised to $385‑$395 million from $365‑$375 million. prnewswire.com
- 4Net loss for the quarter was $4.1 million, including $11.2 million of stock‑based compensation. prnewswire.com
- 5Adjusted EBITDA for Q3 2026 was $12.7 million, compared with $9.2 million a year earlier. prnewswire.com
- 6Net cash provided by operating activities was $19.7 million in the quarter. prnewswire.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.